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THYMOSIN f14 is a polypeptide isolated from thymosin
fraction 5. This peptide exhibits important activities in the
regulation and differentiation of thymus-dependent lym-
phocytes. An analogue of thymosin f14, [Phe(4F)12]deace-
tyl-thymosin f14, was synthesized by a solution method,
followed by deprotection with 1 M trifluoromethane-
sulphonic acid (TFMSA)-thioanisole (molar ratio, 1:1) in
trifluoroacetic acid (TFA) in the presence of dimethl-
selenium. Finally, the deprotected peptide was incubated
with dithiothreitol to reduce sulphoxide on the methionine
side chain. The synthetic [Phe(4F)12]deacetyl-thymosin f14
was found to have a restoring effect on the impaired
blastogenic response of T-lymphocytes isolated from
uraemic patients with recurrent infectious diseases. This
analogue exhibited stronger restorative activity than that
of our synthetic deacetyl-thymosin fig.
Key words: Dithiothreitol reduction, Impaired blastogenic
response, [Phe(4F)12]deacetyl-thymosin 4 synthesis, Re-
storing effect, Trifluoromethanesulphonic acid deprotection,
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Introduction
The impairment of immunological responsive-
ness in uraemic patients is well documented. 1’2 All
aspects of the immune response appear to be
affected by the uraemic state. The numbers,
subpopulations and reactivities of circulating
lymphocytes may be altered by uraemia. 2’3 This
impairment has been implicated in easy suscept-
ibility to infections and increased incidence of
malignancy. In addition, various investigators have
reported severe structural changes in the lymph
nodes4 and thymus glands of uraemic patients and
animals.
The thymus plays an essential role in the
development and maintenance of cellular immune
competence.
6 Recent evidence suggests that the
thymus produces biologically active peptides which
are responsible for the differentiation and functional
maturation of precursor T-lymphocytes.
7
Thymosin f14, an N-terminal acetylated peptide
containing 43 amino acid residues, was first isolated
from calf thymus by Low et al.
8 who determined its
Abbreviations: Z, benzyloxycarbonyl; OBzl, benzyl ester; Bzl,
benzyl; Boc, tert-butoxycarbonyl; Troc, ,,fl-trichloroethoxycarbo-
nyl; Su, N-hydroxysuccinimide; NMM, N-methylmorpholine; OSu,
N-hydroxy-succinimide ester; EDTA, ethylenediaminetetraacetic acid;
DMF, dimethyl-formamide; DMSO, dimethylsulfoxide; AcOH, acetic
acid; MeOH, methanol; EtOAc, ethyl acetate; RPMI, Rosewell Park
Memorial Institute; Phe(4F), p-fluorophenylalanine; HPLC, high-
performance liquid chromatography; DEAE, diethylaminoethyl. PHA,
phytohaemagglutinin.
amino acid sequence. This peptide exhibits
important activities in the regulation and differ-
entiation of thymus-dependent lymphocytes.
8 It
also inhibits the migration of macrophages, and
exerts biological effects on the hypothalamus and
pituitary.
In our previous papers,
11 we reported syntheses
of deacetyl-thymosin f14 and its fragments, and
showed that the synthetic deacetyl-thymosin f14 and
some of the fragments could have restorative effects
on the impaired cell-mediated immunological
functions.
We also noticed that the acetyl group at the
N-terminal serine residue of thymosin f14, is not
required for the restorative effect on the impaired
cell-mediated immunological functions.
9
In our preceding paper,
1 we also concluded that
the two portions of the amino acid sequence of
thymosin /34,-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-
Glu-Lys-Asn- (positions 16-26) and-Lys-Glu-Thr-
Ile-Glu-Gln-Lys-Gln- (positions 31-39), are impor-
tant structures in thymosin f14 for the restoration
activity on impaired cell-mediated immunological
functions and thymosin f14 was effective at lower
concentration than those two synthetic fragments.
So other portions of thymosin f14 may also be
necessary for the full activity.
In 1989, Maeda et a/. 12 reported that one of the
Leu-enkephalin analogues, [Phe(4F)4]Leu-enkeph
alin, showed stronger activity in the guinea-pig
ileum and mouse vas deferens assays as compared
with Leu-enkephalin.
(C) 1992 Rapid Communications of Oxford Ltd Mediators of Inflammation. Vol 1992 113T. A biko and H. Sekino
This result prompted us to synthesize a thymosin
/34 analogue containing a fluorinated aromatic ring.
This paper deals with the synthesis of [Phe(4F)12]
deacetyl-thymosin f14, and an examination of the
immunological effect of this analogue and our
synthetic deacetyl-thymosin 4
9 on the impaired
blastogenic response of T-lymphocytes of uraemic
patients.
Materials and Methods
General experimental procedures used were
essentially the same as described in the previous
papers. 13’14 Preparations of protected intermediates
were repeated several times in order to obtain
sufficient quantities for the next step. Melting points
are uncorrected. Optical rotations were measured
with an Atago Polax machine (cell length: 10 cm).
The amino acid compositions of the acid and
enzymatic hydrolysates were determined with an
Hitachi type 835-50 amino acid analyser. Solutions
were concentrated in a rotary evaporator under
reduced pressure at a temperature of 30-45C.
Boc groups of the protected peptides were
removed by TFA-anisole treatment. The resulting
amino components were chromatographed on silica
gel plates (Kieselgel G, Merck) and RF values refer
to the following solvent system: CHC13-MeOH-
H20 (8:3:1). The final product corresponding to
the entire amino acid sequence of [Phe(4F)12]deace
tyl-thymosin f14 was chromatographed on cellulose
plates (Merck). RF
2 value refers to BuOH-AcOH-
H20 (5:1:1) and RF
3 value refers to BuOH-
pyridine-AcOH-H20 (30:20:6:24). Troc-NHNH2
was purchased from Kokusan Chemical Works
Ltd., Japan. Papain (No. P-3125) and leucine
aminopeptidase (No. L-9876) were purchased from
Sigma Chemical Co.
Preparation ofpeptides
Boc-Lys(Z)-ehe(4F)-NHNH-Troc [I]. Boc-Phe(4F)-
NHNH-Troc (1.9 g) was treated with TFA-anisole
(19 ml-3.8 ml) in an ice bath for 40 min, and TFA
was then removed by evaporation. The residue was
washed with n-hexane, dried over KOH pellets in
vacuo for 2 h, and then dissolved in DMF (10 ml)
containing NMM (0.6ml). To this solution,
Boc-Lys(Z)-OSu (2.1 g) was added, and the mixture
was stirred at room temperature for 7h. The
mixture was extracted with EtOAc and then washed
successively with 5% NaHCO, H20 5O/o citric acid
and H20 dried over MgSO4, and concentrated in
vacuo. The residue was reprecipitated from EtOAc
with n-hexane. Yield 2.2 g (79%), m.p. 81-87C,
[,] --15.3 (c= 1.0, DMF), Rv 0.78, single
ninhydrin-positive spot. Anal. Calcd. for C31H39-
C13FNsOsH20: C, 54.04; H, 6.00; N, 10.16.
Found; C, 53.81; H, 6.29; N, 10.42.
Boc- Glu(OBzl) Lys(Z) Phe(4F) NHNH Troc [II].
This compound was prepared essentially in the
same manner as described for the preparation of I
using I (2.5 g) and Boc-Glu(OBzl)-OSu (1.7 g). The
product was reprecipitated from EtOAc with ether.
Yield 2.7 g (75%), m.p. 103-109C, [] 14.8
(c 1.0, DMF),R 0.82, single ninhydrin-positive
spot. Anal. Calcd. for C43HseC13FN6011 2H20: C,
52.15; H, 5.70; N, 8.49. Found: C, 52.03; H, 6.08;
N, 8.71.
Boc- Ile-Glu(OBzl) Lys(Z) Phe(4F) NHNH Troc
[III]. This compound was prepared from 11 (2.5 g)
and Boc-Ile-OSu (903 mg) essentially as described
for the preparation of I. The product was
reprecipitated from EtOAc with ether. Yield 2 g
(71%), m.p. 130-136C, [] -8.7 (c= 1.0,
DMF), R 0.84, single ninhydrin-positive spot.
Anal. Calcd. for C49H63C13FN7012 2H20: C, 53.34;
H, 6.12; N, 13.73. Found: C, 53.11; H, 6.49;
N, 13.80.
Boc Glu(OBzl) Ile Glu(OBzl) Lys(Z) Phe(4F)
NHNH-Troc [IV]. This compound was prepared
from 1II (1.6 g) and Boc-Olu(OBzl)-OSu (683 mg)
essentially as described for the preparation of I. The
product was reprecipitated from acetone with ether.
Yield 1.4 g (74%), m.p. 103-110C, [] --12.6
(c 1.0, DMF),R 0.84, single ninhydrin-positive
spot. Anal. Calcd. for C61H76C13FN805 3H20: C,
54.65; H, 6.17; N, 8.36. Found: C, 54.42; H, 6.41;
N, 8.59.
Boc Ala Glu(OBzl) Ile Glu(OBzl) Lys(Z)
Phe(4F)-NHNH-Troc []. This compound was
prepared fromI (1.3 g) and Boc-Ala-OSu (3.1 g)
essentially as described for the preparation of I. The
product was reprecipitated from EtOAc with ether.
Yield 1.1 g (79%), m.p. 132-139C, [] --11.4
(c 1.0, DMF), R 0.85, single ninhydrin-positive
spot. Anal. Calcd. for C64H81C13FN9016 4H20: C,
53.80; H, 6.27; N, 8.82. Found: C, 53.60; H, 6.37;
N, 8.45.
Boc-Met(O) Ala- Glu(OBzl) Ile- Glu(OBzl) Lys(Z)-
Phe(4F)-NHNH-Troc [I]. Compound (1 g) was
treated with TFA-anisole (10 ml-2 ml) as described
above. Boc-Met(O)-Su (272 mg) was added to a
solution of this product in DMF (10 ml), followed
by NMM to keep the solution slightly alkaline.
After 8 h at room temperature, the reaction mixture
was poured into 5% NaHCO3 with stirring. The
precipitate thereby formed was washed successively
with 5% NaHCO3, H20, citric acid and H20. The
dried product was reprecipitated from MeOH with
ether. Yield 986 mg (88%), m.p. 130-137C, []
-7.3 (c 1.0, DMF), RF 0.80, single ninhydrin-
positive spot. Anal. Calcd. for C69H90C13FN100sS
5H20: C, 51.96; H, 6.32; N, 8.78. Found: C, 51.71;
H, 6.54; N, 8.97.
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Boc Asp(OBzl) Met(O) Ala Glu(OBzl) Ile
Glu(OBzl)-Lys(Z)-Phe(4F)-NHNH-Troc [VIII. This
compound was prepared from VI (798 mg) and Boc-
Asp(OBzl)-OSu (232 mg) essentially as described
for the preparation of VI. The dried product
was reprecipitated from hot EtOAc. Yield 765 mg
(86%), m.p. 150-158C, [0] zI) 11.4 (c 1.0,
DMF), RF 0.86, single ninhydrin-positive spot.
Anal. Calcd. for CsoH101C13FNO21S 4H20: C,
53.92; H, 6.17; N, 8.65. Found: C, 53.75; H, 6.44;
N, 8.59.
Boc Asp(OBzl) Met(O) Ala Glu(OBzl) Ile
Glu(OBzl)-Lys(Z)-Phe(4F)-NHNH2 [1II Com-
pound VII (594 mg) in a mixture of acOH ( m)
andDMF (6 ml) was treated with zinc dust (220 mg)
at4Cfor 12 h. Thesolutionwasfiltered,thefiltratewas
concentrated in vacuo, and the residue was treated
with 3% EDTA and then with NaHCO3 to adjust
the pH to neutral. The resulting powder was
washed with H20 and reprecipitated from DMF
with H20. Yield 487 mg (91%), m.p. 178-186C,
[0] -19.4 (c= 1.0, DMF), RF 0.76, single
hydrazine-test-positive spot. Anal. Calcd. for
C77H100FN109S 4H20: C, 57.56; H, 6.78; N, 9.59.
Found: C, 57.46; H, 6.91; N, 9.41.
Boc Asp(OBzl) Met(O) Ala Glu(OBzl) Ile
Olu(OBzl)-Lys(Z)-Phe(4F)-asp(OBzl)-Lys(Z)- Ser(Bzl)-
Lys(Z)-Leu Lys(Z) Lys(Z) Thr(Bzl) Glu(OBzl)
Thr(Bzl) Gin- Glu(OBzl) Lys(Z) -Asn Pro- Leu-
Pro Ser(Bzl) Lys(Z) Glu(OBzl) Thr(Bzl) Ile-
Glu(OBzl) Gin Glu(OBzl) Lys(Z) Gin Ala Gly
Gu(OBzl) Ser(Bzl) OBzl [IX]. This compound
was prepared as follows: Boc- Asp(OBzl) Lys(Z)
Ser(Bzl) Lys(Z) Leu- Lys(Z) Lys(Z) Thr(Bzl)
Olu(OBzl) Thr(Bzl) Gin- Olu(OBzl) Lys(Z)
Asn- Pro- Leu- Pro- Ser(Bzl) Lys(Z) glu(OBzl)
Thr(Bzl) Ile- Olu(OBzl) Gin- Olu(OBzl) Lys(Z)
Gin- Ala- Gly- Glu(OBzl)- Ser(Bzl)-OBzl (151 mg)
was treated with TFA-anisole (2 ml-O.4 ml) as usual
and dissolved in DMF-DMSO (1:1, 3 ml) contain-
ing NMM (0.03 ml). The azide [prepared from
121 mg of VIII (3 eq)] in DMF-DMSO (1:1, 2 ml)
and NMM (0.042 ml) were added to the above
ice-chilled solution and the mixture was stirred at
-10C for 36 h until the solution became
ninhydrin-negative. After addition of a few drops
of AcOH, the mixture was poured into 5% citric
acid with stirring. The resulting powder was
washed with 5% citric acid, H20 and MeOH and
purified by gel filtration on Sephadex LH-60 using
DMSO containing 3% H20 as an eluent. The
desired fractions (each 5 ml, tube nos 45-56) were
combined, the solvent was evaporated off, and the
residue was treated with MeOH to afford a powder.
Yield 139 mg (75%), m.p. 184--195C, [] -18.3
(c= 1.0, DMSO), RF 0.82, single ninhydrin-
positive spot. Anal. Calcd. for C380H4-z6FNsO89S
13H20: C, 61.12; H, 6.78; N, 9.57. Found: C,
60.85; H, 6.96; N, 9.58. Amino acid ratios in a 6N
HC1 hydrolysate: Gly 1.00, Leu 2.09, Ile 0.95,
Met(O) 0.94, Ala 2.04, Pro 1.91, Phe(4F) 0.93, Ser
2.89, Thr 2.91, Glu 10.86, Asp. 2.94, Lys 7.95
(recovery of Gly 86%).
Boc- Ser(Bzl) Asp(OBzl) Lys(Z) Pro- Asp(OBzl)-
Met(O)-Ala-Glu(OBzl)-Ile-Glu(OBzl)-Lys(Z) Phe(4F)-
Asp(OBzl)-Lys(Z)-Ser(Bzl)-Lys(Z)-Leu-Lys(Z)-Lys(Z)-
Thr(Bzl) Olu(OBzl) Thr(Bzl) Gin- Olu(OBzl) Lys(Z)-
Asn Pro Leu Pro Ser(Bzl) Lys(Z) Glu(OBzl)-
Thr(Bzl) Ile Glu(OBzl) Gin Glu(OBzl) Lys(Z) Gln-
Ala-Gly-Glu(OBzl)-Ser(Bzl)-OBzl [X]. Compound IX
(93 mg) was treated with TFA-anisole (2 ml-0.4 ml)
as usual and dissolved in DMF-DMSO (1:1, 3 ml)
containing NMM (0.015 ml). The azide [prepared
from 33mg of Boc-Ser(Bzl)-Asp(OBzl)-Lys(Z)-
Pro-NHNH29 (3 eq)] in DMF-DMSO (1:1, 2 ml)
and NMM (0.05 ml) were added to the above
ice-chilled solution and the mixture was stirred at
-10C for 36h. Additional azide (1 eq) in
DMF-DMSO (1:1, 2 ml) and NMM (0.016 ml) was
then added and stirring was continued for an
additional 24 h until the solution became ninhydrin-
negative. After addition of a few drops of AcOH,
the mixture was poured into 5% citric acid with
stirring. The resulting powder was washed with 5%
citric acid, H20 and MeOH. The product was
reprecipitated from DMSO with MeOH. Yield
65 mg (63%), m.p. 181-192C, [0] -23.8
(c= 1.0, DMSO), RF 0.86, single ninhydrin-
positive spot. Anal. Calcd. for C420Hse3FN56098S
17H20: C, 60.92; H, 6.78; N, 9.47. Found: C,
60.57; H, 6.83; N, 9.43. Amino acid ratios in a 6N
HC1 hydrolysate: Gly 1.00, Leu 1.97, Ile 1.94,
Met(O) 0.92, Ala 2.05, Pro 2.88, Phe(4F) 0.90, Ser
3.89, Thr 2.91, Glu 11.03, Asp 3.94, Lys 8.98
(recovery of Gly 84%).
H- Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-
Phe(4F)-Asp-Lys- Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-
Gln-Glu-Lys-Asn-Pro-Leu-Pro- Ser-Lys-Glu-Thr- Ile-
Glu-Gln- Glu- Lys-Gln- Ala-Gly- Glu- Ser-OH (corre-
sponding to [Phe(4F)12]deacetyl-thymosin f14 [Xl]. The
protected tritetracontapeptide ester X (50 mg) was
treated with 1 M TFMSA-thioanisole in TFA (2 ml)
in the presence of MeiSe (50/,tl) in an ice bath for
120 min, then dry ether was added. The resulting
powder was collected by centrifugation, dried over
KOH pellets for 2 h and dissolved in 1 N AcOH
(5 ml). After being stirred with Amberlite IRA-400
(acetate form, approximately 1 g) for 30 min, the
solution was adjusted to pH 6.0 with 1 N AcOH
and the solution was lyophilized. The residue was
dissolved in H20 (5 ml). The solution, after
addition of dithiothreitol (10 mg), was incubated at
60C for 36 h. The solvent was evaporated in vacuo
and the residue was dissolved in a small amount of
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1% AcOH and then applied to a column of
Sephadex G-25 (2.4 x 93 cm), which was eluted
with 1% AcOH. Individual fractions (4 ml each)
were collected and the absorbance at 260 nm was
determined for each fraction. The fractions
corresponding to the first main peak (tube
nos 52-61) were combined and the solvent was
removed by lyophilization. The residue was
dissolved in H20 (2 ml) and the solution was
applied to a column of DEAE-cellulose (Brown,
2.4 x 50cm), eluted with a linear gradient of
400 ml each of H20 and 0.08 M NH4HCO3 buffer
at pH 7.8. Individual fractions (4 ml each) were
collected and the absorbance at 260nm was
determined. The main peak present in the gradient
eluates (tube nos 69-77) were combined and the
solvent was condensed to approximately 2 ml. This
solution was then applied to a column of Sephadex
G-25 (2.4 x 93 cm), which was eluted with 1%
AcOH. The desired fractions (4 ml each, tube nos
50-59) were collected and the solvent was removed
by lyophilization to give a fluffy powder. Yield
7.1 mg (24%) [] --79.3 (c 0.3, 1 N AcOH),
RF
2 0.01, RF
3 0..08, single ninhydrin- and chlorine-
tolidine-positive spot. The synthetic peptide exhi-
bited a single spot on a paper electrophoresis: Toyo
Roshi No. 51 (2 x 40 cm) at pH 7.1 pyridinium-
acetate buffer; mobility, 1.5 cm from the origin
toward the anode, after running at 2 mA, 600 V for
80 min. The synthetic peptide exhibited a single
peak on HPLC using an analytical Nucleosil 5C18
column (4 x 150mm) at a retention time of
15.48 min, when eluted with a gradient of
acetonitrile (20-45%) in 0.1% TFA at a flow rate
of 1 ml/min (Fig. 3). Amino acid ratios in a 6 N
HC1 hydrolysate: Gly 1.00, Leu 2.04, Ile 1.97, Met
0.89, Ala 2.05, Pro 2.84, Phe(4F) 0.92, Ser 3.87, Thr
2.89, Glu 10.96, Asp 3.88, Lys 9.02 (recovery of
Gly 86%). Amino acid ratios in papain plus leucine
aminopeptidase digest: Gly 1.00, Leu 2.06, Ile 2.03,
Met 0.87, Ala 2.01, Pro 2.85, Phe(4F) 0.94, Ser 3.90,
Thr 2.91, Glu 7.89, Asp 2.95, Lys 3.92; Gin and
Asn were not determined (recovery of Gly 84%).
Patient selection: Two uraemic patients who were
suffering from recurrent infectious diseases were
selected. Examination of the cellular immuno-
competence of these patients revealed a significant
decrease in blast formation by PHA.
Thymidine incorporation values of these patients
were 9081 and 10 748 cpm, respectively (normal
values: 38 692-39 463 cpm). Venous blood was
obtained from these uraemic patients for the blast
formation test. Venous blood samples from three
healthy donors were used as a control. HPLC was
conducted with a Shimadzu LC-3A apparatus
equipped witha Nucleosil 5C18 column.
Blast formation test: PHA-P (Difco) was added at
optimal concentration of 1/zg/ml. T-lymphocytes
were cultured in 0.2 ml of RPMI 1640 plus 10%
foetal calf serum in microtitre plates (Falcon No.
3040). Then 0.02 ml (final 1/lg/ml) of PHA was
added, with either the synthetic [Phe(4F)le]deacetyl-
thymosin/34 or control peptide (deacetyl-thymosin
/g4). Triplicate cultures of each combination of
5 x 105 cells per well were incubated at 37C in a
humidified atmosphere at 5% COg in air for 3 days.
Before harvest (24 h), 1 #Ci of [3H].-thymidine was
added per culture. The amount of thymidine
incorporation into DNA was measured in a
scintillation counter (Table 1).
Results
From a synthetic viewpoint, compared with our
previous syntheses of deacetyl-thymosin/349 and its
fragments,1’11 the thioanisole-mediated TFMSA
deprotection procedure
13 was applied in the final
step of the present synthesis instead of catalytic
hydrogenation or hydrogen fluoride.
Our synthetic route to [Phe(4F)12]deacetyl-
thymosin /34 is illustrated in Fig. 1, which shows
three fragments selected as building blocks to
[2] Boc-Ser(Bzl)-Asp(OBzl)-Lys(Z)-Pro-NHNH2
[VlI]Boc-Asp(OBzl)-Met(O)-Ala-Glu(OBzl)-Ile-Glu(OBzl)-
C
Lys(Z)-Phe(4F)-NHNH-Troc
[1] Bc-As(Bz)-Lys(Z)-ser(Bz)-ys(Z)-eu-Lys(Z)-ys(Z)-Thr(Bz)-Gu(Bz)-Thr(Bz)-Gn-Gu(Bz)-
Ala_Gly_Glu(OBzl)_Ser(Bzl)_OBzl
a
1. M TFMSA-thioanisole-Me2Se in TFA
2. Dithiothreitol
H-Ser-Asp-Lys-Pro-Asp-Met-Aa-Gu-Ie-Gu-Lys-Phe(4F)-Asp-Lys-er-Lys-Leu-Lys-Lys-Thr-Gu-Thr-GIn-Gu-Lys-Asn-Pr-Leu-Pr-Ser-
Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH
FIG. 1. Synthetic route to [Phe(4F)12]deacetyl-thymosin fl,. a: TFA-anisole; b, azide; c, Zn-AcOH.
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construct the entire amino acid sequence of
[Phe(4F)12]deacetyl-thymosin /4. Of these, two
fragments, [1] and [2], are those employed for our
previous synthesis of deacetyl-thymosin 4 o9 Thus,
one fragment [VIII, which covers the area of
sequence variation between deacetyl-thymosin /4
and [Phe(4F)12]deacetyl-thymosin /4, was newly
synthesized.
Amino acid derivatives bearing protecting
groups removable by 1 M TFMSA-thioanisole in
TFA
13 were employed, i.e. Ser(Bzl), Thr(Bzl),
Lys(Z), Glu(OBzl), Asp(OBz) and Ser(Bzl)-OBzl.
The Met residue was reversibly protected as its
sulphoxide in order to prevent partial S-alkylation
during the N%TFA deprotection as well as partial
air oxidation during the synthesis. The Boc group,
removable by TFA, was adopted as a temporary
N%protecting group for every intermediate. The
substituted hydrazine, Troc-NHNH2,
is was em-
ployed for the preparation of a fragment [VII],
Boc- Asp(OBzl) Met(O)- Ala- Glu(OBzl) Ile-
Olu(OBzl)-Lys(Z)-Phe(4F)-NHNH-Troc, contain-
ing the Glu(OBzl) and Asp(OBzl) residues. This
Troc group is known to be cleaved by zinc
is in
AcOH without affecting other functional groups.
Throughout the synthesis, the purity of every
intermediate was checked by thin-layer chromat-
ography, elemental analysis and amino acid analysis
of acid hydrolysates. The analytical results were
within -t- 0.4% of theoretical values in all
cases.
The protected octapeptide fragment [VII],
Boc-(5-12)-NHNH-Troc, was prepared stepwise by
the Su active ester procedure to yield Boc-
Asp(OBzl)-Met(O)-Ala-Glu(OBzl)-Ile-Glu(OBzl)-
Lys(Z)-Phe(4F)-NHNH-Wroc [VIII, and the Boc
groups of intermediates were removed by treatment
with TFA-anisole prior to the next coupling
reaction. The protected octapeptide fragment [VII]
thus obtained was treated with zinc
is in AcOH to
remove the Troc group, and the zinc acetate was
removed by treatment with EDTA to give the
required hydrazide, Boc-(5-12)-NHNH2 [VIII], in
an analytically pure form. The hydrazine test on the
thin-layer chromatogram and elemental analysis
data were consistent with homogeneity of the
desired product. The three fragments were
successively condensed by the azide procedure
according to the route shown in Fig.1.
Every reaction was carried out in a mixture of
DMF and DMSO and the amount of the acyl
component was increased from three to four
equivalents as the chain elongation progressed.
Every product was purified either by precipitation
from DMSO with MeOH or by gel filtration on
Sephadex LH-60. Throughout the synthesis, Gly
was used as a diagnostic amino acid in acid
hydrolysis. By comparison of recovery of Gly with
1.0
0.5
10 20 30 40 50 60 70 80 90
Tube nos.
FIG. 2. Purification of synthetic [Phe(4F)12]deacetyl-thymosin f14 by
ion-exchange chromatography on a DEAE-cellulose column.
those newly incorporated amino acids, satisfactory
incorporation of each fragment was ascertained.
In the final step of the synthesis, the protected
tritetracontapeptide ester was treated with 1 M
TFMSA-thioanisole in TFA in the presence of
MeiSe, which was employed to facilitate acidic
cleavage of protecting groups. The unprotected
peptide was next precipitated with peroxide-free
ether, converted to the corresponding acetate with
Amberlite IRA-400 (acetate form) and then treated
with 1 N NH4OH at pH 8.0 to reverse a possible
N O shift at the Ser and Thr residues. The Met
(O) residue was reduced back to Met in two steps,
firstly with thioanisole and MeiSe during the above
acid treatment, and secondly with dithiothreitol
during incubation of the unprotected peptide. The
reduced product was purified by gel filtration on
Sephadex G-25, followed by ion-exchange column
FIG. 3. HPLC of synthetic [Phe(4F)12]deacetyl-thymosin
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Table 1. Effect of the synthetic deacetyl-thymosin f14 and [Phe(4F)12]deacetyl-thymosin f14 on the impaired PHA stimulation of
T-lymphocytes of uraemic patients
Reaction mixture No. of Dose of peptide [3H]-thymidine
determ )tions (#g/ml) incorporation
(cpm)
A only 3 406 _+ 36
B only 3 39 077 _+ 3 418
C only 3 9 915 _+ 3 219
Deacetyl-thymosin f14 + C 3 0.1 9 862 +_ 3 197
Deacetyl-thymosin/Y4 + C 3 1.0 19 628 4- 3 192
[Phe(4F)12]deacetyl-thymosin f14 + C 3 0.1 26 187 _+ 3 248
[Phe(4F)2]deacetyl-thymosin f14 + C 3 1.0 30 119 _+ 3 186
H-Gly-Gly-Lys-OH + C 3 1.0 9 628 _+ 3 119
A" Normal lymphocytes, PHA(-)" B" normal lymphocytes, PHA(+)" C" uraemic patient’s lymphocytes, PHA(+). All incubations
were carried out at 37C in a humidified atmosphere of 5% CO2 in air for 12 h. The control, H-Gly-Gly-Lys-OH, was purchased from
the Peptide Insitute Inc., Osaka.
chromatography on a DEAE-cellulose column with
linear gradient elution using pH 7.8 NH4HCO3
buffer, followed by Sephadex G-25 column
chromatography and the solvent was removed by
lyophilization. The product exhibited a single spot
(ninhydrin- and chlorine-tolidine-positive) on TLC
in two different solvent systems and paper
electrophoresis (pH 7.1 pyridinium acetate buffer).
Its purity was further confirmed by amino acid
analysis after acid hydrolysis and enzymatic
digestion. The synthetic peptide exhibited a single
peak on HPLC.
The immunological effect of the synthetic
deacetyl-thymosin 49 and [Phe(4F)12]deacetyl-thy
mosin f14 was examined by means of the lymphocyte
stimula,tion test by PHA.
16 Responses of T-
lymphocytes to mitogenic stimulation were lower
in uraemic patients than those of normal persons.
The in vitro effect of the two synthetic peptides on
the impaired PHA response of T-lymphocytes from
uraemic patients is shown in Table 1.
Comparison of the amount of [3H]-thymidine
incorporation into DNA shows that, in the case of
the uraemic patients investigated, not only the
synthetic deacetyl-thymosin 4
9 but also the
synthetic [Phe(4F)le]deacetyl-thymosin f14 exhibited
restoring effect.
Interestingly, our synthetic [Phe(4F)li]deacetyl
thymosin f14 showed stronger restoring activity than
that of our synthetic deacetyl-thymosin f14. In this
study, the strong electron withdrawing fluoride
group on the para position of the aromatic ring
results in an analogue that possesses stronger
activity than that of the parent molecule.
Maeda et al. also reported
12 that [Phe(4F)4] Leu-
enkephalin showed stronger activity in the
guinea-pig ileum and mouse vas deferens assays as
compared with Leu-enkephalin. These results
might suggest that modification of the Phe residue
of thymosin f14 could produce more potent
analogues capable of a restorative effect on impaired
blastogenic response of T-lymphocytes.
Discussion
We have reported
9-11 evidence of impaired
immune function in patients with chronic uraemia.
This impairment is reflected in both in vitro and in
vivo depressed cell-mediated immune function.
Patients with chronic uraemia may have thymic
atrophy. The thymus may show a marked reduction
in lymphoid elements and extensive replacement
infiltration with fat. Cystic degradation may be seen.
These observations and findings suggested to us
that the cell-mediated immune abnormalities seen
in chronic uraemia might be attributable to thymic
hormone deficiency. The test involves the in vitro
incubation of patient lymphocytes with the
synthetic peptides and the results of incubations
with the [Phe(4F)12]deacetyl-thymosin f14 and
deacetyl-thymosin f14 are compared.
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